FDA authorizes BioNTech and Pfizer’s COVID-19 booster for 16- and 17-year-olds


The Food and Drug Administration said 16- and 17-year-olds can now get booster doses of BioNTech SE BNTX, -2.65% and Pfizer Inc.’s PFE, +1.32% COVID-19 vaccine. BioNTech’s stock was down 0.1% in trading on Thursday, while Pfizer shares gained 1.7%. The FDA’s decision is an expansion of the authorization of the BioNTech/Pfizer booster for all adults back in mid-November. This is the only booster shot authorized for this age group in the U.S. So far this year, BioNTech’s stock has soared 257.6%, while shares of Pfizer are up 42.1%. The S&P 500 SPX, -0.72% is up 25.1% this year.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleC.H. Robinson increases dividend
Next articleEarnings Results: Broadcom stock rallies more than 5% on aggressive plan to return shareholder cash, earnings beat


Please enter your comment!
Please enter your name here